Oxygen Biotherapeutics announces CRADA Agreement amendment
Links shared publicly online about this topic.
- 860total visits
Oxygen Biotherapeutics announces CRADA Agreement amendment
Oxygen Biotherapeutics, Inc. today announced it has amended an existing Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC) to include preclinical trials using swine models to assess the safety and efficacy of Oxygen Biotherapeutics' proprietary Oxycyte perfluorocarbon emulsion (PFCE) for spinal cord injury (SCI) due to decompression sickness (DCS), and for hemorrhagic shock.
View full resource at news-medical.net
Tags: Disease and Condition
Most Recently Shared on September 20, 2010 at 6:41 am By:
Oxygen Biotherapeutics announces CRADA Agreement amendment: Oxygen Biotherapeutics, Inc. today announced it has am... http://bit.ly/97pAQI
Advertisement
